OUTCOME OF BOARD MEETING HELD ON 17TH MAY 2025 FOR THE APPROVAL OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDING 31ST MARCH 2025
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics' board approved audited financial results for Q4 FY25 and the full year ended March 31, 2025. Revenue from operations fell to Rs 31,823 lakhs in FY25 from Rs 36,859 lakhs in FY24, a decline of around 13.7%. The company, however, turned around to a standalone net profit of Rs 354.61 lakhs in FY25 compared to a net loss of Rs 904.89 lakhs in FY24. Consolidated net profit stood at Rs 672.07 lakhs versus a loss of Rs 907.17 lakhs earlier, helped by lower finance costs and improved operating margins. The statutory auditor V.S. Somani & Co. issued an unqualified opinion with no modified remarks. The board also appointed M/s. Ragini Chokshi & Co. as secretarial auditor for FY 2025-26. A pending scheme of merger of Mangalam Laboratories Pvt Ltd and Shri JB Pharma Pvt Ltd with the company awaits NCLT approval.
Shareholders get a cleaner earnings picture: the company swung from a loss to a modest profit, and operating cash flow strengthened to Rs 42.76 crore. However, the top line shrank and margins appear thin, so investors should watch revenue recovery and the outcome of the pending merger before drawing strong conclusions on the stock.